Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Charles Longwell

Neurology Columbus, OH Medical Doctor

NPI 1740406883 CMS profile 868196

5965 E Broad St, Suite 260, Columbus, OH 43213

Open in the dashboard

General payments

$515

30 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Longwell of Columbus, OH is reported in the CMS Open Payments database as having received $515 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $108 5
2023 General $260 17
2022 General $131 7
2020 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Longwell
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Charles Longwell were reported at $108. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Charles Longwell Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $16 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $131 $442 $103–$2,388 $149
2023 $260 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $108 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $292 18 payments
  2. Allergan Inc. $38 2 payments
  3. Argenx US, Inc. $29 1 payment
  4. US WorldMeds, LLC $25 1 payment
  5. SK Life Science, Inc. $22 1 payment
  6. Lundbeck LLC $19 1 payment
  7. Axsome Therapeutics, Inc. $18 1 payment
  8. Novartis Pharmaceuticals Corporation $17 1 payment
  9. Neurelis, Inc. $14 1 payment
  10. Horizon Therapeutics plc $14 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $515 30 payments
Products named General payments · program years 2020–2025
  1. QULIPTA $146 9 payments
  2. UBRELVY $134 8 payments
  3. BOTOX Hyperhydrosis $50 2 payments
  4. BOTOX Botox Therapeutic $40 3 payments
  5. VYVGART Hytrulo $29 1 payment
  6. BOTOX Neuroscience $29 2 payments
  7. GOCOVRI $25 1 payment
  8. VYEPTI $19 1 payment
  9. DUOPA $18 1 payment
  10. Symbravo $18 1 payment
  11. Other $72 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,643

Median for Neurology: 833

Drug cost

$68,300

Median for Neurology: $202,670

Branded share of claims

15.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 161 $18,356
Aimovig Autoinjector Erenumab-Aooe Brand 11 $11,988
Levetiracetam Generic 84 $5,220
Gabapentin Generic 195 $4,112
Carbamazepine Er Carbamazepine Brand 15 $2,664
Carbidopa-Levodopa Carbidopa/Levodopa Brand 82 $2,221
Topiramate Generic 119 $1,866
Lacosamide Generic 15 $1,787
Baclofen Generic 69 $1,735
Donepezil Hcl Generic 136 $1,503

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$63,669

Medicare's payments for the services billed

Medicare patients

261

Average age 74

Services billed

5,846

151 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Depression 44%
Diabetes 41%
Chronic kidney disease 38%
Ischemic heart disease 36%
Atrial fibrillation 30%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record